loading page

Infantile Hemangiomas: A Tertiary Referral Center Institutional Experience and Analysis of Propranolol Usage
  • +2
  • Andrea Lopez A,
  • Georgina Sellyn E,
  • Heidi Chen,
  • Dana R. Janssen,
  • James D. Phillips
Andrea Lopez A
Vanderbilt University School of Medicine
Author Profile
Georgina Sellyn E
Vanderbilt University School of Medicine
Author Profile
Heidi Chen
Vanderbilt University Medical School Section of Surgical Sciences
Author Profile
Dana R. Janssen
Monroe Carell Junior Children's Hospital at Vanderbilt
Author Profile
James D. Phillips
Monroe Carell Junior Children's Hospital at Vanderbilt

Corresponding Author:[email protected]

Author Profile

Abstract

Introduction Oral propranolol is a first-line treatment for infantile hemangiomas (IH). This study aims to describe the results of treating IH with propranolol only or initial propranolol therapy followed by laser therapy, surgical excision, corticosteroid therapy, or a second cycle of propranolol. Methods Our patient population included pediatric patients (<18 years of age) diagnosed with IH at Monroe Carell Junior Children’s Hospital at Vanderbilt University Medical Center between August 2009 to July 2017. Patient demographics, IH clinical features, and treatment data were extracted from the electronic medical record. Results Three hundred forty patients with IH were included in this study, with a prevalence of focal lesions (71%) and a total of 279 (82%) IH located on the head/neck. Lesions of the head had a statistically significant association with PHACE syndrome (p<0.001). Most patients initiated propanolol treatment before the age of 6 months (71%), with continuation for ≥6 months (69%). Upon discontinuation of propranolol, 14 (4%) patients required a second cycle of propranolol for regrowth. After controlling for IH location, patients with a family history of hemangiomas or cardiac abnormalities were 3.6 times more likely to need a second round of propranolol treatment (OR, 3.6; 95% Confidence Interval 1.14-11.19) (P=0.03). Conclusion The study confirms propranolol’s effectiveness and safety, reinforcing the need for early intervention and close monitoring following treatment termination to prevent regrowth. Ultimately, this research contributes to advancing the understanding and treatment of IH, aiming to optimize patient outcomes and reduce morbidity.
19 Sep 2023Submitted to Clinical Otolaryngology
24 Oct 2023Submission Checks Completed
24 Oct 2023Assigned to Editor
31 Oct 2023Reviewer(s) Assigned